Hemispherx Biopharma Inc. (HEB)

0.44
0.01 1.39
AMEX : Health Technology
Prev Close 0.45
Open 0.45
Day Low/High 0.44 / 0.46
52 Wk Low/High 0.30 / 0.84
Volume 190.64K
Avg Volume 787.70K
Exchange AMEX
Shares Outstanding 36.14M
Market Cap 15.58M
EPS -0.30
P/E Ratio 1.66
Div & Yield N.A. (N.A)

Latest News

Hemispherx Announces Data Presentation On The Potential For Ampligen To Improve Cancer Outcomes With Checkpoint Inhibitors

Hemispherx Announces Data Presentation On The Potential For Ampligen To Improve Cancer Outcomes With Checkpoint Inhibitors

Multiple Studies Continue to Demonstrate Broad Immunotherapeutic Properties of Hemispherx's Ampligen

Hemispherx Comments On $500+ Million Market Opportunity For Ampligen®, The Only Late Stage ME/CFS Candidate In The U.S.

Hemispherx Comments On $500+ Million Market Opportunity For Ampligen®, The Only Late Stage ME/CFS Candidate In The U.S.

Ampligen® has orphan drug status in the U.S. for treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Hemispherx Enters Into Sale/Leaseback Agreement For NJ Development And Production Facility

Hemispherx Enters Into Sale/Leaseback Agreement For NJ Development And Production Facility

Transaction helps boost Ampligen production to maximum levels

Hemispherx Enhances Manufacturing Efficiency Of Ampligen

Hemispherx Enhances Manufacturing Efficiency Of Ampligen

New Technology Simplifies, Speeds Production of Immuno-Oncology Candidate

Hemispherx Announces Presentation Of New-Found Properties Of Ampligen At Immuno-Oncology Frontiers Conference, Jan 24

Hemispherx Announces Presentation Of New-Found Properties Of Ampligen At Immuno-Oncology Frontiers Conference, Jan 24

Ampligen from Hemispherx Shows Potential to Make Tumors More Responsive to Checkpoint Inhibitors

Hemispherx Biopharma, Inc. Presentation Now Available For On-Demand Viewing

Hemispherx Biopharma, Inc. Presentation Now Available For On-Demand Viewing

Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view the presentation

Hemispherx Human Safety Study Of Intranasal Ampligen® With Influenza Vaccine Shows Ampligen Was Generally Well-Tolerated

Hemispherx Human Safety Study Of Intranasal Ampligen® With Influenza Vaccine Shows Ampligen Was Generally Well-Tolerated

Earlier Primate Studies Showed Enhanced Protection and Rodent Studies Showed Cross-Protection in Influenza Models

Hemispherx Biopharma To Host Conference Call To Discuss Second Quarter Financial Results On Tuesday, August 15, 2017

Hemispherx Biopharma To Host Conference Call To Discuss Second Quarter Financial Results On Tuesday, August 15, 2017

Financials for Second Quarter Ended June 30, 2017 will be released on August 14, 2017

Hemispherx Encouraged By Cytokine Biomarker Discovery Which May Lead To A Diagnostic For Chronic Fatigue Syndrome

Hemispherx Encouraged By Cytokine Biomarker Discovery Which May Lead To A Diagnostic For Chronic Fatigue Syndrome

Cytokine Signatures Could Lead to the First Empirical Measure of Disease Severity in Chronic Fatigue Syndrome

Hemispherx Updates Status Of Immuno-Oncology Program In Pancreatic Cancer

Hemispherx Updates Status Of Immuno-Oncology Program In Pancreatic Cancer

12 Pancreatic Cancer Patients Receiving Ampligen® Immuno-Oncology Therapy in Early Access Program

Hemispherx Biopharma Repurposes Ampligen In Immuno-Oncology

Joseph C. Horvath, M.D., Named Deputy Chief Medical Officer to Oversee Ampligen European Pancreatic Cancer Programs

Hemispherx Biopharma Enhances Ampligen Manufacturing And Scientific Capabilities

Promotes Carol Smith, Ph.D., to Chief Manufacturing Officer and Deputy Chief Scientific Officer

Hemispherx Biopharma Announces Financial Results For The Three Months Ended March 31, 2017

The company has generated revenues from the lots of newly manufactured Ampligen

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

TheStreet's biotech columnist offers his own report card on biotech stocks.

TheStreet Quant Rating: D (Sell)